Skip to main content

We've saved some files called cookies on your device. These cookies are:

  • essential for the site to work
  • to help improve our website by collecting and reporting information on how you use it

We would also like to save some cookies to help tailor communications.

BETA
You're viewing an updated version of this service - your feedback will help us to improve it.

15 Voluntary ex ante Transparency (VEAT) Notice

PICCOS TRIAL

  • First published: 11 May 2023
  • Last modified: 11 May 2023
  • Record interest

     

  • This file may not be fully accessible.

  •  

Contents

Summary

OCID:
ocds-kuma6s-131480
Published by:
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
Authority ID:
AA0221
Publication date:
11 May 2023
Deadline date:
-
Notice type:
15 Voluntary ex ante Transparency (VEAT) Notice
Has documents:
No
Has SPD:
No
Has Carbon Reduction Plan:
N/A

Abstract

This trial aims to determine if a new way of delivering chemotherapy as a spray, directly into the peritoneal cavity, might improve survival in patients with peritoneal metastases, compared to conventional intravenous chemotherapy. CPV: 79314000, 79314000.

Full notice text

Voluntary ex ante transparency notice

Directive 2014/24/EU

Section I: Contracting entity

I.1) Name and addresses

NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

4-5 Charnwood Court,, Heol Billingsley, Parc Nantgarw

Cardiff

CF15 7QZ

UK

Telephone: +44 1443848585

E-mail: rhodri.poacher@wales.nhs.uk

NUTS: UK

Internet address(es)

Main address: http://nwssp.nhs.wales/ourservices/procurement-services/

Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

PICCOS TRIAL

Reference number: CAV-STA (22-23) 212

II.1.2) Main CPV code

79314000

 

II.1.3) Type of contract

Services

II.1.4) Short description

This trial aims to determine if a new way of delivering chemotherapy as a spray, directly into the peritoneal cavity, might improve survival in patients with peritoneal metastases, compared to conventional intravenous chemotherapy.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement

Value excluding VAT: 1 974 920.41  GBP

II.2) Description

II.2.2) Additional CPV code(s)

79314000

II.2.3) Place of performance

NUTS code:

UKL22


Main site or place of performance:

University Hospital of Wales.

II.2.4) Description of the procurement

Bowel, ovarian and stomach cancer often spreads to the lining of the abdominal cavity. This trial aims to determine if a new way of delivering chemotherapy as a spray, directly into the peritoneal cavity, might improve survival in patients with peritoneal metastases, compared to conventional intravenous chemotherapy. Critically, we will also assess the impact of treatment on patient quality of life.

Up to 13%, 50% and 14% of patients with bowel, ovarian and stomach cancer respectively, present with

peritoneal metastases. When this form of spread occurs, patients are normally told their disease is

incurable. As well as a relatively rapid decline, peritoneal metastases can cause a series of unpleasant

symptoms due to new tumour growth. Peritoneal metastases are difficult to treat with conventional anticancer drugs and there is an urgent need to develop new treatment strategies. A new strategy showing

potential is Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC). PIPAC delivers anti-cancer

drugs into the peritoneal cavity as an aerosol during keyhole surgery. PIPAC has been shown to deliver

higher doses of chemotherapy directly to tumour sites compared to conventional treatment, with fewer

side-effects due to less chemotherapy circulating in the blood. PIPAC has been shown to be both safe and feasible in a series of clinical trials. The question that now remains is whether PIPAC is efficacious

or not.

PIPAC has excited much interest in patient groups. CAV will disseminate study results through social

media, relevant charitable organisations, presentation at academic conferences, peer-reviewed journals

as well as through the trial web page hosted at the Centre for Trials Research. Information leaflets,

public presentations and media coverage are integral elements of our public engagement plans. The

results will strongly influence a future NICE review of PIPAC in the UK.

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition

Justification for selected award procedure:

The procurement falls outside the scope of application of the Directive

Explanation:

This contract will be awarded to the Cardiff University, who have senior personnel with a large amount of experience in this area of research who are leading on this research project.

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V: Award of contract/concession

Contract No: CAV-STA (22-23) 212

V.2 Award of contract/concession

V.2.1) Date of conclusion of the contract/concession

11/05/2023

V.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

CARDIFF UNIVERSITY

CARDIFF UNIVERSITY, 30 36 NEWPORT ROAD

CARDIFF

CF240DE

UK

NUTS: UK

The contractor is an SME: No

V.2.4) Information on value of the concession and main financing terms (excluding VAT)

Total value of the concession/lot: 1 974 920.41  GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information

This VEAT will be in place for 10 calendar days from 11th May 2023 until 22nd May 2023.

NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at http://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=131480.

(WA Ref:131480)

VI.4) Procedures for review

VI.4.1) Review body

High Court

Royal Courts of Justice, The Strand

London

WC2A 2LL

UK

Telephone: +44 2079477501

VI.5) Date of dispatch of this notice

11/05/2023

Coding

Commodity categories

ID Title Parent category
79314000 Feasibility study Market research services

Delivery locations

ID Description
1022 Cardiff and Vale of Glamorgan

Alert region restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

ID Description
There are no alert restrictions for this notice.

About the buyer

Main contact:
rhodri.poacher@wales.nhs.uk
Admin contact:
N/a
Technical contact:
N/a
Other contact:
N/a

Further information

Date Details
No further information has been uploaded.

0800 222 9004

Lines are open 8:30am to 5pm Monday to Friday.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.